Search
Alnylam Pharmaceuticals Inc
ALNYAdd to Watchlist
293.520USD
+2.150+0.74%
Close 06/29, 16:00（ET）Quotes delayed by 15 min
39.17BMarket Cap
71.84P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.74%
5 Days
+5.55%
1 Month
-3.78%
6 Months
-26.73%
Year to Date
-26.19%
1 Year
-9.08%
Key Figures
296.970Open
298.060High
1.37MVolume
71.84P/E TTM
24.81P/E Dynamic
--Dividend TTM
1.02%Turnover Ratio
291.370Prev. Close
291.900Low
305.88MTurnover
LossP/E Static
36.42P/B
0.00%Div Yield TTM
11.52%ROA
495.55052wk High
1.06Volume Ratio
-278.16MNet Profit
133.44MShares
4.0857EPS TTM
0.29Beta
90.36%ROE
284.28052wk Low
2.11%Amplitude
81.91%Gross Margin
39.17BMarket Cap
-1.72Reward/Risk
2.05%Risk Rate
TradingKey Stock Score of Alnylam Pharmaceuticals Inc
Currency: USD Updated: 2026-06-26Key Insights
Alnylam Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 53 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 445.42.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Alnylam Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Alnylam Pharmaceuticals Inc Highlights
StrengthsRisks
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 103.14% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 71.31, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 133.66M shares, decreasing 4.33% quarter-over-quarter.
Held by Ray Dalio
Star Investor Ray Dalio holds 119.30K shares of this stock.
Analyst Rating
Based on
31
analysts
Buy
Current Rating
445.420
Target Price
+52.87%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Alnylam Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Alnylam Pharmaceuticals Inc Info
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Ticker SymbolALNY
CompanyAlnylam Pharmaceuticals Inc
CEOGreenstreet (Yvonne L)
Websitehttps://www.alnylam.com/
Related Instruments
+1.74%
+1.48%
+1.38%
+0.30%
+0.56%
+1.38%
+0.62%
+0.56%
-1.21%
+0.39%
+1.69%
+1.79%
+0.59%
+1.12%
-2.09%
0.00%
-0.17%
+2.85%
-0.74%
+0.47%Popular Instruments
52153.200
+401.000 (+0.78%)
29707.700
+720.200 (+2.48%)
7432.200
+100.200 (+1.37%)
15451.000
+169.000 (+1.11%)
70474.000
+966.000 (+1.39%)
6255.800
+48.700 (+0.79%)
70.316
+0.168 (+0.24%)
281.740
-2.040 (-0.72%)
194.970
+2.440 (+1.27%)
4015.590
-72.170 (-1.77%)
FAQs
What is the current price of Alnylam Pharmaceuticals Inc (ALNY)?
The current price of Alnylam Pharmaceuticals Inc (ALNY) is 291.37.
What is the symbol of Alnylam Pharmaceuticals Inc?
The ticker symbol of Alnylam Pharmaceuticals Inc is ALNY.
What is the 52-week high of Alnylam Pharmaceuticals Inc?
The 52-week high of Alnylam Pharmaceuticals Inc is 495.55.
What is the 52-week low of Alnylam Pharmaceuticals Inc?
The 52-week low of Alnylam Pharmaceuticals Inc is 284.28.
What is the market capitalization of Alnylam Pharmaceuticals Inc?
The market capitalization of Alnylam Pharmaceuticals Inc is 38.90B.
Is Alnylam Pharmaceuticals Inc (ALNY) currently rated as Buy, Hold, or Sell?
According to analysts, Alnylam Pharmaceuticals Inc (ALNY) has an overall rating of Buy, with a price target of 445.42.
What is the Earnings Per Share (EPS TTM) of Alnylam Pharmaceuticals Inc (ALNY)?
The Earnings Per Share (EPS TTM) of Alnylam Pharmaceuticals Inc (ALNY) is 2.39.
